Use of the Paradigm 722 System to Improve Glycemic Control in Adult and Adolescent Subjects With Type 1 Diabetes
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Scott W Lee, MD
Medtronic
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Children'S Hospital of Los Angeles
Los Angeles, California, United States
- Stanford University
Stanford, California, United States
- Atlanta Diabetes Associates
Atlanta, Georgia, United States
- Joslin Diabetes Center
Boston, Massachusetts, United States
- the Endocrine Group
Albany, New York, United States
- Diabetes and Glandular Diabetes Research Associates
San Antonio, Texas, United States
- University of Washington
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Jun 2005
- Primary completion
- 31 Aug 2006
- Completion
- 28 Feb 2007
- Last update posted
- 12 Jun 2017
- Registered enrollment
- 146
- Registry id
- NCT00211510
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.